162 related articles for article (PubMed ID: 34816383)
1. Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.
Musiek ACM; Rieger KE; Bagot M; Choi JN; Fisher DC; Guitart J; Haun PL; Horwitz SM; Huen AO; Kwong BY; Lacouture ME; Noor SJ; Rook AH; Seminario-Vidal L; Vermeer MH; Kim YH
Dermatol Ther (Heidelb); 2022 Jan; 12(1):29-40. PubMed ID: 34816383
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
[TBL] [Abstract][Full Text] [Related]
3. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
4. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
5. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
Tawa M; Kopp E; McCann S; Cantrell W
Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
[TBL] [Abstract][Full Text] [Related]
6. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
Porcu P; Hudgens S; Horwitz S; Quaglino P; Cowan R; Geskin L; Beylot-Barry M; Floden L; Bagot M; Tsianakas A; Moskowitz A; Huen A; Dreno B; Dalle S; Caballero D; Leoni M; Dale S; Herr F; Duvic M
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):97-105. PubMed ID: 33158772
[TBL] [Abstract][Full Text] [Related]
7. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
Lewis DJ; Rook AH
Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
[TBL] [Abstract][Full Text] [Related]
8. An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report.
L'Orphelin JM
Ther Adv Hematol; 2024; 15():20406207241235777. PubMed ID: 38456078
[TBL] [Abstract][Full Text] [Related]
9. CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver.
Nicolay JP; Albrecht JD; Alberti-Violetti S; Berti E
Eur J Immunol; 2021 Jul; 51(7):1660-1671. PubMed ID: 33811642
[TBL] [Abstract][Full Text] [Related]
10. Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma.
Watson S; Marx JB
J Adv Pract Oncol; 2019; 10(8):883-888. PubMed ID: 33425472
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
Kasamon YL; Chen H; de Claro RA; Nie L; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Dec; 25(24):7275-7280. PubMed ID: 31366601
[TBL] [Abstract][Full Text] [Related]
12. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
Beygi S; Duran GE; Fernandez-Pol S; Rook AH; Kim YH; Khodadoust MS
Blood; 2022 Jun; 139(26):3732-3736. PubMed ID: 35436328
[TBL] [Abstract][Full Text] [Related]
13. Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study.
Jouandet M; Nakouri I; Nadin L; Kieny A; Samimi M; Adamski H; Quéreux G; Chaby G; Dompmartin A; L'Orphelin JM
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406431
[TBL] [Abstract][Full Text] [Related]
14. Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series.
Trum NA; Zain J; Martinez XU; Parekh V; Afkhami M; Abdulla F; Carson KR; Rosen ST; Bennett CL; Querfeld C
Br J Dermatol; 2022 Jan; 186(1):153-166. PubMed ID: 34427917
[TBL] [Abstract][Full Text] [Related]
15. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.
Ollila TA; Sahin I; Olszewski AJ
Onco Targets Ther; 2019; 12():1085-1094. PubMed ID: 30799938
[TBL] [Abstract][Full Text] [Related]
16. Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
Horwitz S; Zinzani PL; Bagot M; Kim YH; Moskowitz AJ; Porcu P; Dwyer K; Sun W; Herr FM; Scarisbrick J
Leuk Lymphoma; 2021 Dec; 62(13):3109-3118. PubMed ID: 34304674
[TBL] [Abstract][Full Text] [Related]
17. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome.
Roelens M; de Masson A; Andrillon A; Ram-Wolff C; Biard L; Boisson M; Mourah S; Battistella M; Toubert A; Bagot M; Moins-Teisserenc H
Br J Dermatol; 2022 Jun; 186(6):1010-1025. PubMed ID: 35041763
[TBL] [Abstract][Full Text] [Related]
18. Histopathologic Characterization of Mogamulizumab-associated Rash.
Wang JY; Hirotsu KE; Neal TM; Raghavan SS; Kwong BY; Khodadoust MS; Brown RA; Novoa RA; Kim YH; Rieger KE
Am J Surg Pathol; 2020 Dec; 44(12):1666-1676. PubMed ID: 32976123
[TBL] [Abstract][Full Text] [Related]
19. Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with Sézary syndrome.
Breen ID; Brumfiel CM; Patel MH; Rosenthal AC; Rule WG; DiCaudo DJ; Craig FE; Pittelkow MR; Mangold AR
JAAD Case Rep; 2021 Mar; 9():24-27. PubMed ID: 33604439
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial.
Cowan RA; Scarisbrick JJ; Zinzani PL; Nicolay JP; Sokol L; Pinter-Brown L; Quaglino P; Iversen L; Dummer R; Musiek A; Foss F; Ito T; Rosen JP; Medley MC
J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):2225-2238. PubMed ID: 34273208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]